The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial
Open accessAbstract
BACKGROUND: Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. METHODS: In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. FINDINGS: Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50). INTERPRETATION: Dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance. FUNDING: UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
Self-citationThe epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action
Di Cesare, M., Sorić, M., Bovet, P., Miranda, J. J., Bhutta, Z., Stevens, G. A., Laxmaiah, A., Kengne, A.-P., & Bentham, J. (2019) · BMC Medicine · doi:10.1186/s12916-019-1449-8 · Cited by 1,090
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
Phyo, A. P., Nkhoma, S., Stepniewska, K., Ashley, E. A., Nair, S., McGready, R., ler Moo, C., Al-Saai, S., Dondorp, A. M., Lwin, K. M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60484-x · Cited by 924
Self-citationGenetic diversity and chloroquine selective sweeps in Plasmodium falciparum
Wootton, J. C., Feng, X., Ferdig, M. T., Cooper, R. A., Mu, J., Baruch, D. I., Magill, A. J., & Su, X.-Z. (2002) · Nature · doi:10.1038/nature00813 · Cited by 722
Combination approaches to combat multidrug-resistant bacteria
Worthington, R. J., & Melander, C. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.006 · Cited by 625
Genetic architecture of artemisinin-resistant Plasmodium falciparum
Miotto, O., Amato, R., Ashley, E. A., MacInnis, B., Almagro-Garcia, J., Amaratunga, C., Lim, P., Mead, D., Oyola, S. O., Dhorda, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3189 · Cited by 609
Self-citationThe public health impact of chloroquine resistance in Africa
Trape, J. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.12 · Cited by 521
Intercontinental Spread of Pyrimethamine-Resistant Malaria
Roper, C., Pearce, R., Nair, S., Sharp, B., Nosten, F., & Anderson, T. (2004) · Science · doi:10.1126/science.1098876 · Cited by 510
Amaratunga, C., Lim, P., Suon, S., Sreng, S., Mao, S., Sopha, C., Sam, B., Dek, D., Try, V., Amato, R., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00487-9 · Cited by 493
Self-citationImwong, M., Suwannasin, K., Kunasol, C., Sutawong, K., Mayxay, M., Rekol, H., Smithuis, F. M., Hlaing, T. M., Tun, K. M., van der Pluijm, R. W., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30048-8 · Cited by 484
Self-citation
Cited by
Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria
Wicht, K. J., Mok, S., & Fidock, D. A. (2020) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115546 · Cited by 322
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines
Al Khaja, K. A. J., & Sequeira, R. P. (2021) · Malaria Journal · doi:10.1186/s12936-020-03565-2 · Cited by 39
Saito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02002-8 · Cited by 25
Self-citationNayak, S., Peto, T. J., Kucharski, M., Tripura, R., Callery, J. J., Quang Huy, D. T., Gendrot, M., Lek, D., Nghia, H. D. T., van der Pluijm, R. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54915-6 · Cited by 15
Self-citationMalaria – Current Treatment Options
Virginia, D. M., Shegokar, R., & Pathak, Y. (2023) · Malarial Drug Delivery Systems · doi:10.1007/978-3-031-15848-3_4 · Cited by 1
Metadata
- Authors
- van der Pluijm, R. W., Tripura, R., Hoglund, R. M., Pyae Phyo, A., Lek, D., ul Islam, A., Anvikar, A. R., Satpathi, P., Satpathi, S., Behera, P. K., Tripura, A., Baidya, S., Onyamboko, M., Chau, N. H., Sovann, Y., Suon, S., Sreng, S., Mao, S., Oun, S., Yen, S., Amaratunga, C., Chutasmit, K., Saelow, C., Runcharern, R., Kaewmok, W., Hoa, N. T., Thanh, N. V., Hanboonkunupakarn, B., Callery, J. J., Mohanty, A. K., Heaton, J., Thant, M., Gantait, K., Ghosh, T., Amato, R., Pearson, R. D., Jacob, C. G., Gonçalves, S., Mukaka, M., Waithira, N., Woodrow, C. J., Grobusch, M. P., van Vugt, M., Fairhurst, R. M., Cheah, P. Y., Peto, T. J., von Seidlein, L., Dhorda, M., Maude, R. J., Winterberg, M., Thuy-Nhien, N. T., Kwiatkowski, D. P., Imwong, M., Jittamala, P., Lin, K., Hlaing, T. M., Chotivanich, K., Huy, R., Fanello, C., Ashley, E., Mayxay, M., Newton, P. N., Hien, T. T., Valecha, N., Smithuis, F., Pukrittayakamee, S., Faiz, A., Miotto, O., Tarning, J., Day, N. P. J., White, N. J., Dondorp, A. M., van der Pluijm, R. W., Tripura, R., Hoglund, R. M., Phyo, A. P., Lek, D., ul Islam, A., Anvikar, A. R., Satpathi, P., Satpathi, S., Behera, P. K., Tripura, A., Baidya, S., Onyamboko, M., Chau, N. H., Sovann, Y., Suon, S., Sreng, S., Mao, S., Oun, S., Yen, S., Amaratunga, C., Chutasmit, K., Saelow, C., Runcharern, R., Kaewmok, W., Hoa, N. T., Thanh, N. V., Hanboonkunupakarn, B., Callery, J. J., Mohanty, A. K., Heaton, J., Thant, M., Gantait, K., Ghosh, T., Amato, R., Pearson, R. D., Jacob, C. G., Gonçalves, S., Mukaka, M., Waithira, N., Woodrow, C. J., Grobusch, M. P., van Vugt, M., Fairhurst, R. M., Cheah, P. Y., Peto, T. J., von Seidlein, L., Dhorda, M., Maude, R. J., Winterberg, M., Thuy-Nhien, N. T., Kwiatkowski, D. P., Imwong, M., Jittamala, P., Lin, K., Hlaing, T. M., Chotivanich, K., Huy, R., Fanello, C., Ashley, E., Mayxay, M., Newton, P. N., Hien, T. T., Valeche, N., Smithuis, F., Pukrittayakamee, S., Faiz, A., Miotto, O., Tarning, J., Day, N. P., White, N. J., & Dondorp, A. M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 395
- Issue
- 10233
- Pages
- 1345-1360
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3012441801
- Cited by
- 271
- References
- 31
- FWCI
- 30.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30552-3
- The paper
- van der Pluijm, R. W., Tripura, R., Hoglund, R. M., Pyae Phyo, A., Lek, D., ul Islam, A., Anvikar, A. R., Satpathi, P., Satpathi, S., Behera, P. K., Tripura, A., Baidya, S., Onyamboko, M., Chau, N. H., Sovann, Y., Suon, S., Sreng, S., Mao, S., Oun, S., . . . Dondorp, A. M. (2020). Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30552-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.